Prognostic Factors Affecting Survival in Malignant Pleural Mesothelioma: Analysis of 125 Subjects
暂无分享,去创建一个
A. Çırak | G. Polat | M. Gayaf | Gunseli Balci | B. Komurcuoglu | O. Usluer | H. Halilçolar | O. Erer | A. Ozsoz | S. Aktoğu | Filiz Guldaval | Nur Yucel | S. Guclu | S. C. Kıraklı
[1] V. Rusch,et al. Initial Analysis of the International Association For the Study of Lung Cancer Mesothelioma Database , 2012, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.
[2] A. Marinaccio,et al. Effects of Combined Therapies on the Survival of Pleural Mesothelioma Patients Treated in Brescia, 1982–2006 , 2012, Tumori.
[3] L. Garland. Chemotherapy for Malignant Pleural Mesothelioma , 2011, Current treatment options in oncology.
[4] M. Metintaş,et al. Prognostic Factors According to the Treatment Schedule in Malignant Pleural Mesothelioma , 2009, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.
[5] J. V. van Meerbeeck,et al. A prognostic index for progression-free survival in malignant mesothelioma with application to the design of phase II trials: a combined analysis of 10 EORTC trials. , 2009, European journal of cancer.
[6] H. Dienemann,et al. Guidelines of the European Respiratory Society and the European Society of Thoracic Surgeons for the management of malignant pleural mesothelioma , 2009, European Respiratory Journal.
[7] M. Metintaş,et al. A retrospective analysis of malignant pleural mesothelioma patients treated either with chemotherapy or best supportive care between 1990 and 2005 A single institution experience. , 2007, Lung cancer.
[8] A. Davies,et al. The Use of Chemotherapy in Patients with Advanced Malignant Pleural Mesothelioma: A Systematic Review and Practice Guideline , 2006, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.
[9] G. Giaccone,et al. Randomized phase III study of cisplatin with or without raltitrexed in patients with malignant pleural mesothelioma: an intergroup study of the European Organisation for Research and Treatment of Cancer Lung Cancer Group and the National Cancer Institute of Canada. , 2005, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[10] I. Uçgun,et al. Prognostic factors in diffuse malignant pleural mesothelioma: effects of pretreatment clinical and laboratory characteristics. , 2001, Respiratory medicine.
[11] V. Roggli,et al. Environmental malignant mesothelioma in southern Anatolia: a study of fifty cases. , 2000, Environmental health perspectives.
[12] J. Herndon,et al. Factors predictive of survival among 337 patients with mesothelioma treated between 1984 and 1994 by the Cancer and Leukemia Group B. , 1998, Chest.
[13] V. Rusch,et al. A proposed new international TNM staging system for malignant pleural mesothelioma from the International Mesothelioma Interest Group. , 1996, Lung cancer.
[14] J. Peto,et al. Continuing increase in mesothelioma mortality in Britain , 1995, The Lancet.
[15] H. Hoogsteden,et al. Prognostic factors and survival in malignant pleural mesothelioma. , 1994, The European respiratory journal.
[16] R. Ginsberg,et al. Diffuse malignant mesothelioma of the pleura in Ontario and Quebec: a retrospective study of 332 patients. , 1989, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[17] E. McFadden,et al. Toxicity and response criteria of the Eastern Cooperative Oncology Group , 1982, American journal of clinical oncology.
[18] L. Norton,et al. Diffuse malignant mesothelioma. Prospective evaluation of 69 patients. , 1982, Annals of internal medicine.
[19] R. Stahel,et al. Malignant pleural mesothelioma: ESMO clinical recommendations for diagnosis, treatment and follow-up. , 2008, Annals of oncology : official journal of the European Society for Medical Oncology.
[20] G. Hillerdal. Staging and evaluating responses in malignant pleural mesothelioma. , 2004, Lung cancer.
[21] P. Janne. Chemotherapy for malignant pleural mesothelioma. , 2003, Clinical lung cancer.
[22] W. Richards,et al. Resection margins, extrapleural nodal status, and cell type determine postoperative long-term survival in trimodality therapy of malignant pleural mesothelioma: results in 183 patients. , 1999, The Journal of thoracic and cardiovascular surgery.
[23] G. Giaccone,et al. Prognostic factors in patients with pleural mesothelioma: the European Organization for Research and Treatment of Cancer experience. , 1998, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[24] E. G. Butchart,et al. Pleural mesothelioma. , 1990, Current opinion in oncology.
[25] R. Shemin,et al. Malignant mesothelioma: prognostic variables in a registry of 180 patients, the Dana-Farber Cancer Institute and Brigham and Women's Hospital experience over two decades, 1965-1985. , 1988, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[26] I. Selikoff,et al. Occupational exposure to asbestos: population at risk and projected mortality--1980-2030. , 1982, American journal of industrial medicine.